solute carrier family 12 member 3Genealiases: NCC · NCCT · TSC
Q-omics provides the consensus-scored SLC12A3 profile across patient tissues and cancer cell-line models. SLC12A3 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, SLC12A3 is differentially expressed in 10, with the highest sampling consensus in KIRC. Additionally, SLC12A3 protein abundance shows 23,127 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight HNSC, KIRC, and LSCC as cancer lineages where SLC12A3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SLC12A3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SLC12A3 survival associations across molecular data types. SLC12A3 RNA expression shows survival associations in the most cancer types (22), followed by mutation status (8) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SLC12A3 RNA expression–survival associations across cancer types. High SLC12A3 expression shows unfavorable associations in UVM and LGG, but favorable associations in HNSC, SKCM, CESC and SARC. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify HNSC as the clearest survival context for SLC12A3 RNA expression.
This table summarizes SLC12A3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10, while mass-spec protein shows differences in 7. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for SLC12A3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SLC12A3 shows lower tumor expression in KIRC, KIRP and KICH and higher tumor expression in LUAD, UCEC and BRCA. The KIRC box plot shows higher SLC12A3 RNA expression in normal versus tumor tissue (log2 FC = −5.866, t-test p < 0.001).
This table shows molecular features associated with SLC12A3 in patient tissues and cancer cell lines. In patient samples, SLC12A3 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, SLC12A3 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BONE, while CRISPR and shRNA rows add functional-dependency signals in PANCREAS and LARGE_INTESTINE.
